Loading...
Will India Soon See Affordable Anti-Obesity Medications?
LIVE TV
LOCAL
Tour
ENGLISH
For You
Entertainment
National
Sports
Markets
Business & Economy
Lifestyle
World
Astrology & Religion
Technology
Education & Jobs
Auto
Politics
Viral
Opinions
Loading more articles...
Home
Local
Live TV
Low-Cost Anti-Obesity Drugs Coming to India as Semaglutide Patent Expires
F
Firstpost
•
18-03-2026, 19:35
Low-Cost Anti-Obesity Drugs Coming to India as Semaglutide Patent Expires
•
The patent on Semaglutide, a key ingredient in weight-loss drugs, expires on March 20, paving the way for generic versions in India.
•
Indian pharma giants Zydus, Torrent Pharma, Sun Pharma, and Dr. Reddy's Laboratories are set to launch generic Semaglutide.
•
Generic anti-obesity drugs are expected to be significantly cheaper, potentially 50-80% below current branded costs, making them more accessible.
•
India faces a severe obesity crisis, with over 23% of women and 22% of men overweight, and is considered the world's diabetes capital.
•
Despite optimism, Semaglutide is not on India's National List of Essential Medicines, meaning patients will pay out of pocket.
Read Full Article on Firstpost in English
✦
More like this
✦
More like this
Diabetes Treatment Revolution: Natco Pharma Launches Affordable Semaglutide in India
N
News18
Obesity Drug Patent Ends: Prices to Drop to Rs 500, A Game-Changer for India
N
News18
Abbott Partners with Novo Nordisk to Launch Extensior, Expanding Diabetes Care in India
M
Moneycontrol
Semaglutide Patent Expires: Generics Flood Market, Prices Plummet 50-70%
M
Moneycontrol
Ozempic Patent Expires: Indian Pharma Unleashes 'Sema' Storm with 50+ Generic Brands, Prices to Halve
N
News18
Lilly to Boost Mounjaro Access in India Amid Rising Obesity
M
Moneycontrol
